Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

The mGluR theory of fragile X mental retardation

Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580

Absence of expression of the FMR-1 gene in fragile X syndrome

Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476

Varieties of Repetitive Behavior in Autism: Comparisons to Mental Retardation

Bodfish, J. W., Symons, F. J., Parker, D. E., & Lewis, M. H. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005596502855 · Cited by 1,223

Correction of Fragile X Syndrome in Mice

Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979

DNA methylation represses FMR-1 transcription in fragile X syndrome

Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.397 · Cited by 680

The Fragile X Syndrome Protein FMRP Associates with BC1 RNA and Regulates the Translation of Specific mRNAs at Synapses

Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S., Oostra, B., & Bagni, C. (2003) · Cell · doi:10.1016/s0092-8674(03)00079-5 · Cited by 676

Advances in the Treatment of Fragile X Syndrome

Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP

Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521

Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X Syndrome

McBride, S. M. J., Choi, C. H., Wang, Y., Liebelt, D. A., Braunstein, E. M., Ferreiro, D., Sehgal, A., Siwicki, K. K., Dockendorff, T. C., Nguyen, H. T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.038 · Cited by 484

Individual differences in reward responding explain placebo-induced expectations and effects

Scott, D. J., Stohler, C. S., Egnatuk, C. M., Wang, H., Koeppe, R. A., & Zubieta, J.-K. (2007) · Neuron · doi:10.1016/j.neuron.2007.06.028 · Cited by 466

Previous Exposure to Nicotine Enhances the Incentive Motivational Effects of Amphetamine via Nicotine-Associated Contextual Stimuli

Cortright, J. J., Sampedro, G. R., Neugebauer, N. M., & Vezina, P. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.80 · Cited by 27

Interpretation of electrokinetic measurements of nanodiamond particles

Petrova, N., Zhukov, A. N., Gareeva, F. R., Koscheev, A. P., Petrov, I., & Shenderova, O. A. (2012) · Diamond and Related Materials · doi:10.1016/j.diamond.2012.10.004 · Cited by 27

Differentiating progressive from nonprogressive T1 bladder cancer by gene expression profiling: Applying RNA-sequencing analysis on archived specimens

Lin, X. S., Hu, L., Sandy, K. Y. P., Correll, M., Quackenbush, J. F., Wu, C., & McDougal, W. S. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.06.014 · Cited by 27

Fragile X syndrome: Lessons learned from the most translated neurodevelopmental disorder in clinical trials

Duy, P. Q., & Budimirovic, D. B. (2017) · Translational Neuroscience · doi:10.1515/tnsci-2017-0002 · Cited by 28

Ultrasensitive DNA Immune Repertoire Sequencing Using Unique Molecular Identifiers

Johansson, G., Kaltak, M., Rîmniceanu, C., Singh, A. K., Lycke, J., Malmeström, C., Hühn, M., Vaarala, O., Cardell, S., & Ståhlberg, A. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa159 · Cited by 27

Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment

Palumbo, J., Thomas, B. F., Budimirovic, D. B., Siegel, S. J., Tassone, F., Hagerman, R. J., Faulk, C. D., O’Quinn, S., & Sebree, T. B. (2023) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-023-09475-z · Cited by 28

Newborn screening and cascade testing for FMR1 mutations

Sorensen, P. L., Gane, L. W., Yarborough, M. A., Hagerman, R. J., & Tassone, F. (2012) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35680 · Cited by 29

Power of Rare Diseases: Found in Translation

Fishman, M. C. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006800 · Cited by 26

Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome

Hessl, D. R., Harvey, D. J., Sansone, S. M., Crestodina, C., Chin, J. A., Joshi, R., Hagerman, R. J., & Berry‐Kravis, E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0209984 · Cited by 26

Cross-Sectional Analysis Investigating the Concordance of Maturity Status Classifications in Elite Caucasian Youth Tennis Players

Myburgh, G. K., Cumming, S. P., & Malina, R. M. (2019) · Sports Medicine - Open · doi:10.1186/s40798-019-0198-8 · Cited by 26

The Aggregation Pattern of Aβ1–40 is Altered by the Presence of N‐Truncated Aβ4–40 and/or CuII in a Similar Way through Ionic Interactions

Stefaniak, E., Atrián‐Blasco, E., Goch, W., Sabater, L., Hureau, C., & Bal, W. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202004484 · Cited by 27

Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics

Newell, K. A., & Matosin, N. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-23 · Cited by 26

Advanced Pharmacotherapy Evidenced by Pathogenesis of Autism Spectrum Disorder

Lee, Y. J., Oh, S. H., Park, C., Hong, M., Lee, A. R., Yoo, H. J., Shin, C. Y., Cheon, K.-A. A., & Bahn, G. H. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.1.19 · Cited by 26

Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes

Wang, H., Pati, S. B. B., Pozzo‐Miller, L. D., & Doering, L. C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00055 · Cited by 28

Data-Driven Discovery of Immune Contexture Biomarkers

Schwen, L. O., Andersson, E. K., Korski, K., Weiss, N., Haase, S., Gaire, F., Hahn, H. K., Homeyer, A., & Grimm, O. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00627 · Cited by 25

Developing a utility index for the Aberrant Behavior Checklist (ABC-C) for fragile X syndrome

Kerr, C., Breheny, K., Lloyd, A. J., Brazier, J. E., Bailey, D. B., Berry‐Kravis, E., Cohen, J., & Petrillo, J. (2014) · Quality of Life Research · doi:10.1007/s11136-014-0759-8 · Cited by 25

Metabolism and Disposition of the Metabotropic Glutamate Receptor 5 Antagonist (mGluR5) Mavoglurant (AFQ056) in Healthy Subjects

Walles, M., Wolf, T., Jin, Y., RITZAU, M., Leuthold, L. A., Krauser, J. A., Gschwind, H.-P., Carcache, D. A., Kittelmann, M., Ocwieja, M., et al. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.050716 · Cited by 25

A quantitative homogeneous assay for fragile X mental retardation 1 protein

Schutzius, G., Bleckmann, D., Kapps-Fouthier, S., Giorgio, F. D., Gerhartz, B., & Weiss, A. (2013) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-5-8 · Cited by 25

Drugs for rare disorders

Cremers, S., & Aronson, J. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13331 · Cited by 24

The perspective from EASAC and FEAM on direct-to-consumer genetic testing for health-related purposes

for the EASAC–FEAM Working Group, Fears, R., Participants in the Working Group were: Stefania Boccia, M. C., & ter Meulen, V. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.238 · Cited by 27

Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody

Monteleone, F., Rosa, R., Vitale, M., DˈAmbrosio, C., Succoio, M., Formisano, L., Nappi, L., Romano, M. F., Scaloni, A., Tortora, G., et al. (2012) · PROTEOMICS · doi:10.1002/pmic.201200303 · Cited by 25

Discovery and Evaluation of a Functional Ternary Polymer Blend for Bone Repair: Translation from a Microarray to a Clinical Model

Khan, F., Smith, J. O., Kanczler, J. M., Tare, R. S., Oreffo, R. O. C., & Bradley, M. (2013) · Advanced Functional Materials · doi:10.1002/adfm.201202710 · Cited by 24

Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome

Brasa, S., Mueller, A., Jacquemont, S., Hahne, F., Rozenberg, I., Peters, T., He, Y., McCormack, C., Gasparini, F., Chibout, S., et al. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0181-x · Cited by 24

Engineering Escherichia coli for Light-Activated Cytolysis of Mammalian Cells

Magaraci, M. S., Veerakumar, A., Qiao, P. L., Amurthur, A., Lee, J. Y., Miller, J. S., Goulian, M., & Sarkar, C. A. (2013) · ACS Synthetic Biology · doi:10.1021/sb400174s · Cited by 24

Learning healthcare systems and rapid learning in radiation oncology: Where are we and where are we going?

Price, G. J., Mackay, R. I., Aznar, M. C., McWilliam, A., Johnson‐Hart, C., van Herk, M., & Finn, C. F. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.09.030 · Cited by 23

Fragile X syndrome: An aging perspective

Schneider, A., Ligsay, A., & Hagerman, R. J. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1129 · Cited by 23

The Case for Phasing Out Experiments on Primates

Conlee, K. M., & Rowan, A. (2012) · The Hastings Center Report · doi:10.1002/hast.106 · Cited by 23

Fragile X–related element 2 methylation analysis may provide a suitable option for inclusion of fragile X syndrome and/or sex chromosome aneuploidy into newborn screening: a technical validation study

Inaba, Y., Herlihy, A. S., Schwartz, C. E., Skinner, C. D., Bui, M., Cobb, J. E., Shi, E. Z., Francis, D. I., Arvaj, A., Amor, D. J., et al. (2012) · Genetics in Medicine · doi:10.1038/gim.2012.134 · Cited by 23

Development of a straightforward and sensitive scale for MCI and early AD clinical trials

Huang, Y., Ito, K., Billing, C. B., Anziano, R., & Initiative, A. D. N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.03.008 · Cited by 23

Behavior in a Drosophila Model of Fragile X

McBride, S. M. J., Bell, A. J., & Jongens, T. A. (2011) · Results and problems in cell differentiation · doi:10.1007/978-3-642-21649-7_6 · Cited by 24

FindingFMR1mosaicism in Fragile X syndrome

Gonçalves, T. F., dos Santos, J. M., Gonçalves, A. P., Tassone, F., Mendoza‐Morales, G., Ribeiro, M. G., Kahn, E., Boy, R. T., Pimentel, M. M. G., & Santos-Rebouças, C. B. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1135739 · Cited by 22

Models in Context: Biological and Epistemological Niches

Bolker, J. A. (2013) · History, philosophy and theory of the life sciences · doi:10.1007/978-94-007-7067-6_8 · Cited by 22

Empowering industrial research with shared biomedical vocabularies

Harland, L., Larminie, C. G. C., Sansone, S., Popa, S., Marshall, M. S., Braxenthaler, M., Cantor, M. N., Filsell, W., Forster, M. J., Huang, E. S., et al. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.013 · Cited by 22

Advances in understanding fragile X syndrome and related disorders

Rooms, L., & Kooy, R. F. (2011) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32834c7f1a · Cited by 22

L’autophagie : le yin et le yang des cancers

Joffre, C., Djavaheri‐Mergny, M., Pattingre, S., & Giuriato, S. (2017) · médecine/sciences · doi:10.1051/medsci/20173303021 · Cited by 24

Humanized mouse models in transplantation research

Hogenes, M. C. H., Huibers, M. M. H., Kroone, C., & de Weger, R. A. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2014.02.002 · Cited by 22

How do researchers manage genetic results in practice? The experience of the multinational Colon Cancer Family Registry

for the Colon Cancer Family Registry, Keogh, L. A., Fisher, D. S., Gorin, S. S., Schully, S. D., Lowery, J. T., Ahnen, D. J., Maskiell, J. A., Lindor, N. M., Hopper, J. L., et al. (2013) · Journal of Community Genetics · doi:10.1007/s12687-013-0148-y · Cited by 22

Platelets as a surrogate disease model of neurodevelopmental disorders: Insights from Fragile X Syndrome

Pellerin, D., Lortie, A., & Corbin, F. (2017) · Platelets · doi:10.1080/09537104.2017.1317733 · Cited by 25

An “Omic” Overview of Fragile X Syndrome

Dionne, O., & Corbin, F. (2021) · Biology · doi:10.3390/biology10050433 · Cited by 24

Developmental programming of energy balance regulation: is physical activity more ‘programmable’ than food intake?

Zhu, S., Eclarinal, J. D., Baker, M. S., Li, G., & Waterland, R. A. (2015) · Proceedings of The Nutrition Society · doi:10.1017/s0029665115004127 · Cited by 23

Effects of AFQ056 on language learning in fragile X syndrome

Berry‐Kravis, E., Abbeduto, L., Hagerman, R. J., Coffey, C. S., Cudkowicz, M., Erickson, C. A., McDuffie, A. S., Hessl, D. R., Ethridge, L. E., Tassone, F., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci171723 · Cited by 24

Characterization of nociceptive behavioural responses in the awake pig following UV – B ‐induced inflammation

Giminiani, P. D., Petersen, L. J., & Herskin, M. S. (2013) · European Journal of Pain · doi:10.1002/j.1532-2149.2013.00340.x · Cited by 21

The Clinical Translation Gap in Child Health Exercise Research: A Call for Disruptive Innovation

Ashish, N., Bamman, M. M., Cerny, F., Cooper, D. M., d’Hemecourt, P. A., Eisenmann, J. C., Ericson, D. A., Fahey, J. T., Falk, B., Gabriel, D. L., et al. (2014) · Clinical and Translational Science · doi:10.1111/cts.12194 · Cited by 21

Liquid Metal Ink Enabled Rapid Prototyping of Electrochemical Sensor for Wireless Glucose Detection on the Platform of Mobile Phone

Yi, L., Li, J., Guo, C., Li, L., & Liu, J. (2015) · Journal of Medical Devices · doi:10.1115/1.4031659 · Cited by 21

Combination Therapy in Fragile X Syndrome; Possibilities and Pitfalls Illustrated by Targeting the mGluR5 and GABA Pathway Simultaneously

Zeidler, S., de Boer, H., Hukema, R. K., & Willemsen, R. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00368 · Cited by 23

Insight on a new indolinone derivative as an orally bioavailable lead compound against renal cell carcinoma

Fouad, M. A., Zaki, M. Y., Lotfy, R. A., & Mahmoud, W. R. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104985 · Cited by 21

Computational Interspecies Translation Between Alzheimer’s Disease Mouse Models and Human Subjects Identifies Innate Immune Complement, TYROBP, and TAM Receptor Agonist Signatures, Distinct From Influences of Aging

Lee, M. J., Wang, C., Carroll, M. J., Brubaker, D. K., Hyman, B. T., & Lauffenburger, D. A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.727784 · Cited by 19

Fast and accurate automated cell boundary determination for fluorescence microscopy

Arce, S. H., Wu, P., & Tseng, Y. (2013) · Scientific Reports · doi:10.1038/srep02266 · Cited by 19

Heterogeneity in Fragile X Syndrome Highlights the Need for Precision Medicine-Based Treatments

Verdura, E., Pérez‐Cano, L., Sabido-Vera, R., Güney, E., Hyvelin, J.-M., Durham, L. A., & Gomez‐Mancilla, B. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.722378 · Cited by 19

Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents.

Baribeau, D. A., & Anagnostou, E. A. (2014) · Europe PMC (PubMed Central) · Cited by 19

Model-Based Evaluation of the Impact of Formulation and Food Intake on the Complex Oral Absorption of Mavoglurant in Healthy Subjects

Wendling, T., Ogungbenro, K., Pigeolet, E., Dumitras, S., Woessner, R., & Aarons, L. J. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1574-1 · Cited by 19

Fragile X Syndrome: An Update on Developing Treatment Modalities

Healy, A. M., Rush, R., & Ocain, T. D. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200019z · Cited by 19

Using Drosophila as a tool to identify pharmacological therapies for fragile X syndrome

McBride, S. M. J., Holloway, S. L., & Jongens, T. A. (2012) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2012.09.005 · Cited by 21

Biomimetic, ultrathin and elastic hydrogels regulate human neutrophil extravasation across endothelial-pericyte bilayers

Lauridsen, H. M., & Gonzalez, A. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171386 · Cited by 19

Unilateral Lateral Epicondylalgia Shows a Pro-nociceptive Pain Profile

Bisset, L., Carty, M., & Smith, A. D. (2018) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000615 · Cited by 19

Rescue of Fmr1 phenotypes with mGluR5 inhibitors: MRZ-8456 versus AFQ-056

Westmark, P. R., Dekundy, A., Gravius, A., Danysz, W., & Westmark, C. J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.008 · Cited by 22

Water soluble nanocurcumin extracted from turmeric challenging the microflora from human oral cavity

Gopal, J., Muthu, M., & Chun, S. (2016) · Food Chemistry · doi:10.1016/j.foodchem.2016.05.140 · Cited by 21

Intramuscular Administration of a Synthetic CpG-Oligodeoxynucleotide Modulates Functional Responses of Neutrophils of Neonatal Foals

Cohen, N. D., Bourquin, J. R., Bordin, A. I., Kuskie, K. R., Brake, C. N., Weaver, K. B., Liu, M., Felippe, M. J. B., & Kogut, M. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109865 · Cited by 18

The Drosophila DmGluRA is required for social interaction and memory

Schoenfeld, B. P., Choi, R. J., Choi, C. H., Terlizzi, A. M., Hinchey, P., Kollaros, M., Ferrick, N. J., Koenigsberg, E., Ferreiro, D., Leibelt, D. A., et al. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00064 · Cited by 17

Fragile X Syndrome: Prevalence, Treatment, and Prevention in China

Niu, M., Han, Y., Dy, A. B. C., Du, J., Jin, H., Qin, J., Zhang, J., Li, Q., & Hagerman, R. J. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00254 · Cited by 19

Should MD–PhD Programs Encourage Graduate Training in Disciplines Beyond Conventional Biomedical or Clinical Sciences?

O'Mara, R. J., Hsu, S. I., & Wilson, D. R. (2014) · Academic Medicine · doi:10.1097/acm.0000000000000540 · Cited by 18

Fragile X syndrome: clinical, cytogenetic and molecular screening among autism spectrum disorder children in Indonesia

Winarni, T. I., Utari, A., Mundhofir, F. E., Hagerman, R. J., & Faradz, S. M. (2013) · Clinical Genetics · doi:10.1111/cge.12095 · Cited by 18

Offering fragile X syndrome carrier screening: a prospective mixed-methods observational study comparing carrier screening of pregnant and non-pregnant women in the general population

Martyn, M. M., Anderson, V. A., Archibald, A. D., Carter, R., Cohen, J., Delatycki, M. B., Donath, S. M., Emery, J. D., Halliday, J. L., Hill, M. K., et al. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003660 · Cited by 18

Dysregulated nitric oxide signaling as a candidate mechanism of fragile X syndrome and other neuropsychiatric disorders

Colvin, S. M., & Kwan, K. Y. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00239 · Cited by 17

Multidimensional single-cell analysis based on fluorescence microscopy and automated image analysis

Sandmann, M., Lippold, M., Saalfrank, F., Odika, C. P., & Rohn, S. (2017) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-017-0344-4 · Cited by 17

Brain circuitry, behavior, and cognition: A randomized placebo-controlled trial of donepezil in fragile X syndrome

Bruno, J. L., Hosseini, S. M. H., Lightbody, A. A., Manchanda, M. K., & Reiss, A. L. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119858304 · Cited by 16

Feasibility, Reproducibility, and Clinical Validity of the Pediatric Anxiety Rating Scale—Revised for Fragile X Syndrome

Russo‐Ponsaran, N. M., Yesensky, J. A., Hessl, D. R., & Berry‐Kravis, E. (2014) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-119.1.1 · Cited by 18

Portfolio Management in New Drug Development

Ding, M., Dong, S., Eliashberg, J., & Gopalakrishnan, A. (2013) · International series in quantitative marketing · doi:10.1007/978-1-4614-7801-0_3 · Cited by 17

Epilepsy drives autism in neurodevelopmental disorders

Hagerman, R. J. (2013) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12071 · Cited by 17

Crosstalk Between SMPDL3b and NADPH Oxidases Mediates Radiation-Induced Damage of Renal Podocytes

Azzam, P., Francis, M., Youssef, T., Mroueh, M., Daher, A. A., Eid, A. A., Fornoni, A., Marples, B., & Zeidan, Y. H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.732528 · Cited by 16

Translational endpoints in fragile X syndrome

de Esch, C. E. F., Zeidler, S., & Willemsen, R. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.10.012 · Cited by 16

Metabotropic Glutamate Receptor 5-negative Allosteric Modulators for the Treatment of Psychiatric and Neurological Disorders (2009–July 2013)

Li, G., J⊘rgensen, M., & Campbell, B. M. (2013) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.13.58 · Cited by 16

Moving Toward Integrative, Multidimensional Research in Modern Psychiatry: Lessons Learned From Fragile X Syndrome

Fung, L. K., & Reiss, A. L. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.015 · Cited by 17

Parent Ratings of Ability to Consent for Clinical Trials in Fragile X Syndrome

Bailey, D. B., Raspa, M., Wheeler, A., Edwards, A., Bishop, E. E., Bann, C., Borasky, D., & Appelbaum, P. S. (2014) · Journal of Empirical Research on Human Research Ethics · doi:10.1177/1556264614540591 · Cited by 16

Guided differentiation and tissue regeneration of induced pluripotent stem cells using biomaterials

Kuo, Y., & Rajesh, R. (2017) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2017.04.043 · Cited by 16

Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men

Beyene, D., Naab, T. J., Kanarek, N., Apprey, V., Esnakula, A. K., Khan, F. A., Blackman, M. R., Brown, C. A., & Hudson, T. (2018) · The Prostate · doi:10.1002/pros.23537 · Cited by 16

The quest for targeted therapy in fragile X syndrome

Zeidler, S., Hukema, R. K., & Willemsen, R. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1079176 · Cited by 15

Alloantigen‐specific regulatory T cells prevent experimental chronic graft‐versus‐host disease by simultaneous control of allo‐ and autoreactivity

Sagoo, P., Ratnasothy, K., Tsang, Y., Barber, L. D., Noble, A., Lechler, R. I., & Lombardi, G. (2012) · European Journal of Immunology · doi:10.1002/eji.201242770 · Cited by 15

The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro

Tabolacci, E., Pirozzi, F., Gomez‐Mancilla, B., Gasparini, F., & Neri, G. (2012) · BMC Medical Genetics · doi:10.1186/1471-2350-13-13 · Cited by 15

Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells

Navai, S. A., & Ahmed, N. M. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150266 · Cited by 16

New Therapeutic Options for Fragile X Syndrome

Jalnapurkar, I. R., Cochran, D., & Frazier, J. A. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0551-8 · Cited by 15

FMR1 mRNA from full mutation alleles is associated with ABC-CFX scores in males with fragile X syndrome

Baker, E. K., Arpone, M., Kraan, C. M., Bui, M., Rogers, C., Field, M. J., Bretherton, L., Ling, L., Ure, A. M., Cohen, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68465-6 · Cited by 14

ESCI award lecture: regulation, function and biomarker potential of DNA methylation

Schübeler, D. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12403 · Cited by 17

Etiology of Autism Spectrum Disorder: A Genomics Perspective

Connolly, J. J., & Hakonarson, H. H. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0501-9 · Cited by 18

Targeted treatments in fragile X syndrome

Hare, E. B., Hagerman, R. J., & Lozano, R. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.903795 · Cited by 14

Assessing excellence in translational cancer research: a consensus based framework

Rajan, A., Caldas, C., van Luenen, H. G. A. M., Saghatchian, M., & van Harten, W. H. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-274 · Cited by 14

Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulators

Bennett, K. A., Christopher, J. A., & Tehan, B. G. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.03.001 · Cited by 14

The research impact of school psychology faculty

Watkins, M. W., & Chan-Park, C. Y. (2015) · Journal of School Psychology · doi:10.1016/j.jsp.2015.03.003 · Cited by 14

An overview of the digital solutions for helping people with aphasia through bibliometric analysis

Asghar, I., Egaji, O. A., & Griffiths, M. (2021) · eNeurologicalSci · doi:10.1016/j.ensci.2021.100311 · Cited by 15

Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice

Ziemba, M., Barkhouse, M., Uaesoontrachoon, K., Giri, M., Hathout, Y., Dang, U. J., Gordish‐Dressman, H., Nagaraju, K., & Hoffman, E. P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246507 · Cited by 14

The right tools for the job: the central role for next generation chemical probes and chemistry-based target deconvolution methods in phenotypic drug discovery

Jörg, M., & Madden, K. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00022e · Cited by 14

Selective expansion of human regulatory T cells in nasal polyps, and not adjacent tissue microenvironments, in individual patients exposed to steroids

Edward, J. A., Sanyal, M., Le, W., Soudry, E., Ramakrishnan, V. R., Bravo, D. T., Nguyen, A. L., Zarabanda, D., Kingdom, T. T., Hwang, P. H., et al. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.02.002 · Cited by 13

Novel substituted 4-(Arylethynyl)-Pyrrolo[2,3-d]pyrimidines negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 5 (mGlu5) Treat depressive disorder in mice

Du, Y., Gao, F., Sun, H., Wu, C., Zhu, G., & Zhu, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115855 · Cited by 14

A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial

de Diego‐Otero, Y., Medina, R. C., Quintero-Navarro, C., Salido, L. S., García-Guirado, F., del Arco, I., Fernández-Carvajal, I., Ferrando-Lucas, T., Caballero‐Andaluz, R., & Pérez-Costillas, L. (2014) · Trials · doi:10.1186/1745-6215-15-345 · Cited by 14

A Novel Analog Reasoning Paradigm: New Insights in Intellectually Disabled Patients

Curie, A., Amandine, B., Cheylus, A., Reboul, A., Nazir, T. A., Bussy, G., Karine, D., Paulignan, Y., Mercier, S., David, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149717 · Cited by 13

Atmospheric-pressure chemical purification of detonation-synthesized nanodiamond by using perchloric acid: Intensive parametric study to control sp3/sp2carbon ratio

Hong, S. P., Ha, S., & Lee, S. W. (2017) · Diamond and Related Materials · doi:10.1016/j.diamond.2017.11.006 · Cited by 13

Impact of early antiretroviral therapy eligibility on HIV acquisition

Oldenburg, C. E., Bor, J. H., Harling, G., Tanser, F. C., Mutevedzi, T., Shahmanesh, M., Seage, G. R., Gruttola, V. D., Mimiaga, M. J., Mayer, K. H., et al. (2018) · AIDS · doi:10.1097/qad.0000000000001737 · Cited by 13

Observational Study of Contracts Processing at 29 CTSA Sites

Kiriakis, J., Gaich, N., Johnston, S. C., Kitterman, D., Rosenblum, D., Salberg, L., & Rifkind, A. (2013) · Clinical and Translational Science · doi:10.1111/cts.12073 · Cited by 13

Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson`s Disease: Bridging Molecular Studies and Clinical Trials

Vallano, A., Fernández‐Dueñas, V., García-Negredo, G., Quijada-Manuitt, M. Á., Simon, C. P., Cuffí, M. L., Carbonell, L., Sánchez, S., Arnau, J. M., & Ciruela, F. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113129990115 · Cited by 13

Targeting Homeostatic T Cell Proliferation to Control Beta-Cell Autoimmunity

Vignali, D., & Monti, P. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0731-9 · Cited by 13

Epigenetic modification of the FMR1 gene in fragile X patients leads to a differential response to the mGluR5 antagonist AFQ056

Jacquemont, S., Curie, A., Portes, V. D., Torrioli, M. G., Berry‐Kravis, E., Hageman, R., Ramos, F. J., Cornish, K. M., He, Y., & neri, G. (2011) · Cited by 2

The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro

Tabolacci, E., Pirozzi, F., Gomez‐Mancilla, B., Gasparini, F., & Neri, G. (2012) · BMC Medical Genetics · doi:10.1186/1471-2350-13-13 · Cited by 15

Progress toward therapeutic potential for AFQ056 in Fragile X syndrome

Doering, L. C., Sourial, M. M., & Cheng, C. (2013) · Journal of Experimental Pharmacology · doi:10.2147/jep.s27044 · Cited by 8

mGlu5 as a potential therapeutic target for the treatment of fragile X syndrome

Robertson, L. (2013) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzt001 · Cited by 1

Fragile X syndrome therapy: to respond or not to respond may be a matter of methylation

Pouladi, M. A. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01663.x · Cited by 1